Valuation: BioRestorative Therapies, Inc.

Market Cap 5.67M 4.86M 4.55M 4.16M 7.85M 540M 7.92M 53.69M 20.9M 273M 21.29M 20.82M 903M P/E 2026 *
-0.45x
P/E 2027 * -0.55x
Enterprise Value 5.67M 4.86M 4.55M 4.16M 7.85M 540M 7.92M 53.69M 20.9M 273M 21.29M 20.82M 903M EV / Sales 2026 *
4.03x
EV / Sales 2027 * 2.45x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+4.36%
1 week+4.46%
Current month+8.70%
1 month-23.28%
3 months+6.97%
6 months-1.16%
Current year-81.06%
1 week 0.21
Extreme 0.21
0.23
1 month 0.19
Extreme 0.19295
0.31
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
3.67
5 years 0.16
Extreme 0.1593
26.8
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 32 2026-07-12
Investor Relations Contact - -
Corporate Officer/Principal - 2025-10-21
Director TitleAgeSince
Director/Board Member 28 2026-06-11
Director/Board Member 37 2026-06-11
Director/Board Member - 2026-07-12
Date Insider Type Main position Quantity % Market Cap.
10/6/25 Free

Chief Technology Officer

23,438 0.2938%
10/6/25 Free

Chief Executive Officer

27,344 0.3427%
2/14/25 Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+4.36%+4.46%-85.26%-90.99% 5.67M
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.96%+2.14%+49.75%+90.89% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-2.49%+6.26%+56.04%+12.49% 27.33B
-0.02%+1.67%+38.70%-16.81% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
0.00%+0.29%+8.11%+544.17% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +1.34%+4.46%+45.25%+168.59% 28.84B
Weighted average by Cap. +1.40%+3.31%+55.70%+155.42%

Financials

2026 *2027 *
Net sales 1.4M 1.2M 1.13M 1.03M 1.94M 134M 1.96M 13.31M 5.18M 67.58M 5.28M 5.16M 224M 2.31M 1.98M 1.86M 1.7M 3.2M 220M 3.23M 21.9M 8.53M 111M 8.68M 8.49M 368M
Net income -13.52M -11.59M -10.86M -9.92M -18.72M -1.29B -18.9M -128M -49.86M -650M -50.78M -49.67M -2.15B -15.56M -13.33M -12.49M -11.41M -21.54M -1.48B -21.75M -147M -57.36M -748M -58.42M -57.15M -2.48B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
26-08-25 $0.2225 +4.36% 103,348
26-08-24 $0.2132 -0.98% 151,870
26-08-21 $0.2153 -2.40% 76,194
26-08-20 $0.2206 +3.42% 192,564
26-08-19 $0.2133 +0.14% 184,405
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2225USD
Average target price
8.000USD
Spread / Average Target
+3,495.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock